@article {504006,
	title = {The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management.},
	journal = {Surv Ophthalmol},
	volume = {61},
	number = {1},
	year = {2016},
	month = {2016 Jan-Feb},
	pages = {1-17},
	abstract = {Ocular inflammatory disease is a leading cause of vision loss worldwide. Uveitis encompasses a wide spectrum of pathology, both with respect to its etiology and the anatomic location within the eye. Inflammation can be confined to the eye and may also be seen systemically. The cornerstone of management of ocular inflammatory disease historically has been corticosteroids, which are invaluable in the immediate control of inflammation; however, corticosteroids are inappropriate for long-term use as they are associated with a wide array of toxic side effects. As we continue to learn more about the various etiologies and elucidate the basic science pathways and mechanisms of action that cause intraocular inflammation, new therapeutic approaches have evolved. They include employment of immunomodulatory agents (corticosteroid-sparing therapies) that have expanded our treatment options for these vision-threatening diseases. These pharmacologics provide therapy for ocular and systemic inflammation in an individualized, patient-tailored, stepladder approach with the ultimate goal of durable, corticosteroid-free remission. We review the preferred practice patterns of a tertiary care center specializing in ocular inflammatory disease.},
	issn = {1879-3304},
	doi = {10.1016/j.survophthal.2015.07.001},
	author = {Foster, C Stephen and Kothari, Srishti and Anesi, Stephen D and Vitale, Albert T and Chu, David and Metzinger, Jamie Lynne and Cer{\'o}n, Olga}
}
